|
Re: Bioasis Announces Investor Relations Service Agreement with Stern IR
|
5
|
BIOASIS TECHNOLOGIES INC
|
Oct 05, 2018 10:33AM
|
|
BD-selectivity vs. BET protein selectivity
|
8
|
Resverlogix Corp.
|
Oct 05, 2018 10:25AM
|
|
Re: David Kideckel now with AltaCorp
|
5
|
Resverlogix Corp.
|
Oct 05, 2018 09:09AM
|
|
Bioasis Announces Investor Relations Service Agreement with Stern IR
|
3
|
BIOASIS TECHNOLOGIES INC
|
Oct 04, 2018 08:20PM
|
|
Re: tiny volume
|
6
|
Resverlogix Corp.
|
Oct 04, 2018 02:08PM
|
|
Re: Blinded Sub Group Data; post by Aureus on IV
|
7
|
Resverlogix Corp.
|
Oct 04, 2018 01:20PM
|
|
Blinded Sub Group Data; post by Aureus on IV
|
6
|
Resverlogix Corp.
|
Oct 04, 2018 12:12PM
|
|
Re: CVOTs on the Horizon
|
5
|
Resverlogix Corp.
|
Oct 04, 2018 11:42AM
|
|
Re: tiny volume
|
4
|
Resverlogix Corp.
|
Oct 03, 2018 05:01PM
|
|
Re: FXR and liver transaminase related adverse events
|
5
|
Resverlogix Corp.
|
Oct 03, 2018 01:41PM
|
|
Re: FXR and liver transaminase related adverse events
|
2
|
Resverlogix Corp.
|
Oct 03, 2018 11:47AM
|
|
Re: FXR and liver transaminase related adverse events
|
5
|
Resverlogix Corp.
|
Oct 03, 2018 11:32AM
|
|
Re: What are the biggest hints that BETonMACE will be a huge success,..
|
2
|
Resverlogix Corp.
|
Oct 02, 2018 02:17PM
|
|
Re: What are the biggest hints that BETonMACE will be a huge success,..
|
3
|
Resverlogix Corp.
|
Oct 02, 2018 01:12PM
|
|
Re: CVOTs on the Horizon
|
3
|
Resverlogix Corp.
|
Oct 02, 2018 10:48AM
|
|
Re: Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains
|
4
|
Zenith Epigenetics
|
Oct 02, 2018 10:27AM
|
|
Re: CVOTs on the Horizon
|
2
|
Resverlogix Corp.
|
Oct 02, 2018 10:02AM
|
|
Re: "Getting cancer drugs into the brain" article in Nature Outlooks mentions BiOasis
|
5
|
BIOASIS TECHNOLOGIES INC
|
Oct 01, 2018 10:20PM
|
|
Re: CVOTs on the Horizon
|
6
|
Resverlogix Corp.
|
Oct 01, 2018 05:48PM
|
|
Re: CVOTs on the Horizon
|
2
|
Resverlogix Corp.
|
Oct 01, 2018 04:22PM
|
